Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) CEO Peter Salzmann sold 16,163 shares of the business’s stock in a transaction that occurred on Wednesday, May 22nd. The stock was sold at an average price of $29.65, for a total transaction of $479,232.95. Following the sale, the chief executive officer now directly owns 1,036,716 shares in the company, valued at approximately $30,738,629.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.
Peter Salzmann also recently made the following trade(s):
- On Wednesday, April 17th, Peter Salzmann sold 34,079 shares of Immunovant stock. The stock was sold at an average price of $29.06, for a total transaction of $990,335.74.
- On Tuesday, April 9th, Peter Salzmann sold 4,807 shares of Immunovant stock. The stock was sold at an average price of $31.18, for a total transaction of $149,882.26.
Immunovant Stock Performance
NASDAQ:IMVT traded up $0.56 during trading hours on Friday, reaching $28.95. 739,078 shares of the company were exchanged, compared to its average volume of 1,145,916. The stock’s 50-day moving average is $30.12 and its 200-day moving average is $35.07. Immunovant, Inc. has a twelve month low of $18.16 and a twelve month high of $45.58.
Institutional Investors Weigh In On Immunovant
Analyst Ratings Changes
IMVT has been the topic of several research analyst reports. Oppenheimer started coverage on shares of Immunovant in a research report on Thursday, March 28th. They set an “outperform” rating and a $50.00 target price on the stock. Truist Financial reaffirmed a “buy” rating and issued a $48.00 price objective on shares of Immunovant in a report on Monday, March 25th. The Goldman Sachs Group started coverage on shares of Immunovant in a report on Wednesday, March 13th. They issued a “buy” rating and a $50.00 price objective on the stock. JPMorgan Chase & Co. started coverage on shares of Immunovant in a report on Tuesday, February 20th. They issued an “overweight” rating and a $51.00 price objective on the stock. Finally, Wolfe Research started coverage on shares of Immunovant in a report on Thursday, February 15th. They issued an “outperform” rating and a $55.00 price objective on the stock. Seventeen analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $49.00.
Check Out Our Latest Analysis on Immunovant
Immunovant Company Profile
Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.
Read More
- Five stocks we like better than Immunovant
- Compound Interest and Why It Matters When Investing
- NASDAQ 100 vs. NASDAQ Composite: A Detailed Breakdown of NASDAQ
- How to Effectively Use the MarketBeat Ratings Screener
- These 2 Retail Traders Favorites are Nearing Major Breakouts
- 3 Warren Buffett Stocks to Buy Now
- Snowflake is Melting… Up, With a Double-Digit Upside Potential
Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.